Carlsmed, Inc. (I82)

Overview

Carlsmed, Inc. is a pioneering medical technology company focused on revolutionizing spine surgery through AI-enabled personalized solutions. The company's principal aim is to enhance patient outcomes while simultaneously reducing healthcare expenses related to spine surgery. This mission is realized through the innovative aprevo® personalized surgery platform, which provides tailored interbody fusion devices and comprehensive 3D surgical planning for a range of spinal procedures, including anterior lumbar interbody fusion (ALIF), lateral lumbar interbody fusion (LLIF), transforaminal lumbar interbody fusion (TLIF), and anterior cervical discectomy and fusion (ACDF).

Carlsmed has significantly advanced the field by being the first company awarded FDA Breakthrough Device Designation for intervertebral spine fusion technology. Since then, it has received additional clearances for both lumbar and cervical systems, as well as CMS NTAP reimbursements. Furthermore, the company has launched sophisticated digital production lines and developed the myaprevo® ecosystem, which fosters a continuous improvement approach to surgical precision and patient care. Under the leadership of co-founder and CEO Mike Cordonnier, and a team of seasoned professionals from notable companies such as NuVasive and Johnson & Johnson, Carlsmed is committed to transforming the treatment of spinal deformities through precise alignment and data-driven methodologies, tackling complex adult deformities one patient at a time, particularly in anticipation of its upcoming 2025 Nasdaq IPO.

Products and Services

• aprevo® Personalized Surgery Platform: This innovative platform is designed to provide customized solutions for spine surgery by integrating AI technology. It empowers surgeons with tailored interbody fusion devices that align with the specific anatomical needs of each patient, alongside detailed 3D surgical planning.
• Interbody Fusion Devices: Carlsmed offers bespoke interbody fusion devices that are crafted to meet individual patient requirements. These devices are essential in procedures like ALIF, LLIF, TLIF, and ACDF, contributing to improved surgical outcomes and recovery times.
• 3D Surgical Planning: The company utilizes advanced 3D imaging and planning technologies to facilitate precise surgical interventions. This service allows surgeons to visualize the procedure step-by-step, enhancing both preparation and execution during surgery.
• myaprevo® Ecosystem: This digital platform integrates various technologies to support ongoing patient care and management. It enables data collection and analysis which helps inform surgical strategies and post-operative care, thus aiming to optimize the overall treatment experience.
• FDA Breakthrough Devices: Carlsmed’s recognition as the first recipient of FDA Breakthrough Device Designation for intervertebral spine fusion technology underscores the innovative nature of its products. This designation enables faster patient access to new technologies that can potentially provide more effective treatments for spine-related conditions.
• CMS NTAP Reimbursements: The inclusion of Carlsmed's technologies within the CMS New Technology Add-on Payment (NTAP) program ensures that healthcare providers can receive additional reimbursements for the innovative treatments offered, facilitating wider patient access to these advanced solutions.
• Digital Production Lines: Carlsmed has deployed advanced digital production lines that allow for scalable and efficient manufacturing of their specialized medical devices. This technology supports precision in the creation of custom solutions tailored to individual anatomical specifications.